Product Description
Mechanisms of Action: ADRA2 Antagonist, 5-HT2 Inverse Agonist, H1 Inverse Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Insomnia|Parasomnias|Menopause|Dyssomnias|Sleep Disorders, Intrinsic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AQUAMARINE | P3 |
Completed |
Insomnia |
2009-11-19 |
2022-03-12 |
||
| 176003/P05721/MK-8265-007 | P3 |
Terminated |
Sleep Disorders, Intrinsic|Parasomnias|Dyssomnias|Insomnia |
2010-03-10 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| JADE | P3 |
Completed |
Insomnia |
2010-02-19 |
2022-03-12 |
Treatments |
|
| Jade | P3 |
Completed |
Sleep Disorders, Intrinsic|Parasomnias|Insomnia|Dyssomnias |
2010-02-14 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| P05709 | P3 |
Completed |
Insomnia|Dyssomnias |
2009-12-21 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| Turquoise | P3 |
Completed |
Insomnia |
2009-12-21 |
2022-03-12 |
Treatments |
|
| 21106/P05701/MK-8265-002 | P3 |
Completed |
Insomnia|Sleep Disorders, Intrinsic|Parasomnias|Dyssomnias |
2009-11-19 |
2024-10-16 |
||
| Aquamarine | P3 |
Completed |
Insomnia |
2009-11-05 |
2022-03-12 |
Treatments |
|
| RUBY | P3 |
Completed |
Insomnia |
2008-08-11 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| P05707 | P3 |
Completed |
Insomnia |
2008-02-13 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| 2004-000469-36 | P3 |
Completed |
Menopause |
2006-01-17 |
2022-03-13 |
Treatments |
|
| 2004-000472-14 | P3 |
Completed |
Menopause |
2006-01-15 |
2022-03-12 |
||
| 46101/P06459/MK-8265-012 | P3 |
Completed |
Menopause |
2006-01-15 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| 177001/P06472/MK-8265-013 | P3 |
Completed |
Menopause |
2006-01-15 |
2024-10-16 |